Literature DB >> 12865590

Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer.

O Drieskens1, S Stroobants, M Gysen, G Vandenbosch, L Mortelmans, I Vergote.   

Abstract

OBJECTIVE: The aim of this prospective study was to evaluate (18)F-FDG-PET, in comparison with CT, for the detection of peritoneal and retroperitoneal metastases of ovarian cancer.
METHODOLOGY: 13 patients with primary (n = 7) or recurrent (n = 6) ovarian cancer underwent an attenuation-corrected (18)F-FDG-PET of the abdomen as well as a contrast-enhanced abdominal CT, followed by surgical staging. For data analysis, the abdomen was artificially divided into six regions (right and left subphrenic region, right and left paracolic gutter, retroperitoneum and central abdomen). All images were reviewed and each region was visually scored on (18)F-FDG-PET as well as on CT. (18)F-FDG-PET results were compared with those of CT, using the surgical data as gold standard.
RESULTS: 73 regions were evaluable surgically and or histologically. Sensitivity was slightly better for CT than for (18)F-FDG-PET (74 vs. 66%). Metastases of <5 mm were missed with both techniques. Specificity, however, was clearly better for (18)F-FDG-PET than for CT (94 vs. 77%), especially in patients with recurrent disease, where postoperative changes (hematomas, adhesions, etc.) caused more false positive results on CT. Retroperitoneal lymph node involvement was found in 3/13 patients. The result of (18)F-FDG-PET for the retroperitoneal lymph nodes was correct in all cases, whereas CT was false positive in 2 patients. (18)F-FDG-PET is relatively inaccurate for the right and the left subphrenic region (missing tumor involvement in 5 patients compared to 2 patients for CT).
CONCLUSION: Given the low sensitivity of both (18)F-FDG-PET and CT for the detection of peritoneal metastases, surgical staging remains the gold standard. Because of the better specificity, (18)F-FDG-PET might be preferred for evaluating residual or recurrent disease after surgery. (18)F-FDG-PET was more sensitive in the retroperitoneal region than intraperitoneal. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12865590     DOI: 10.1159/000071525

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  6 in total

1.  What is the pelvic lymph node normal size? Determination from normal MRI examinations.

Authors:  Marjorie Ramirez; Pierre Ingrand; Jean-Pierre Richer; Guillaume Herpe; Guillaume Vesselle; Samy Boucebci; Jean-Pierre Tasu
Journal:  Surg Radiol Anat       Date:  2015-10-29       Impact factor: 1.246

2.  Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer.

Authors:  G Mangili; M Picchio; S Sironi; R Viganò; E Rabaiotti; D Bornaghi; V Bettinardi; C Crivellaro; C Messa; F Fazio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-20       Impact factor: 9.236

Review 3.  Positron Emission Tomography (PET) in Oncology.

Authors:  Andrea Gallamini; Colette Zwarthoed; Anna Borra
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

4.  Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings.

Authors:  Hyun Hoon Chung; Won Jun Kang; Jae Weon Kim; Noh-Hyun Park; Yong-Sang Song; June-Key Chung; Soon-Beom Kang; Hyo-Pyo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-07       Impact factor: 9.236

5.  Value of 18F-FDG PET in the detection of peritoneal carcinomatosis.

Authors:  Akiko Suzuki; Tsuyoshi Kawano; Nobukazu Takahashi; Jin Lee; Yoshihiro Nakagami; Etsuko Miyagi; Fumiki Hirahara; Shinji Togo; Hiroshi Shimada; Tomio Inoue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-16       Impact factor: 9.236

6.  Ovarian mass mimicking malignancy: a case report.

Authors:  Yong-Il Kim; Seok-Ki Kim; Jeong-Won Lee; Sang Mi Lee; Tae-Sung Kim
Journal:  Nucl Med Mol Imaging       Date:  2010-08-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.